Optimizing RSV Treatment: Insights into Targeted Drug Delivery Strategies and Public Health Implications

Respiratory Syncytial Virus (RSV) remains a pressing health issue worldwide, with infants, young children, and elderly individuals, especially vulnerable. In the present study, we reviewed available treatment modalities, Their efficacy rates were measured, and possible improvements of both therapeutic methods and pharmacological delivery methods were explored. Through analysis of recent literature and data, we evaluated the current efficacy of bronchodilators, anti-inflammatory agents, and monoclonal antibodies work in RSV treatment. Notably, while bronchodilators and corticosteroids only offer monoclonal antibodies, such as Palivizumab, confer preventive benefits among those at high risk but with limited alleviation. Additionally, emerging therapeutic options—such as RNA interference and nucleoside analogs—have demonstrated initial potential in thereby minimizing RSV replication. These findings emphasize the need for targeted therapy that is not only specific but also effective in reducing the complications and mortality burden caused by RSV. Others, like Palivizumab, are showing prospects for high-risk groups, RNA interference treatments may offer a new strategy in directly targeting viral replication. Perhaps the best route to reduction incorporates both prevention and direct intervention in a multifaceted approach. Development of RSV, and further research into siRNA-based therapies with enhanced drug delivery. Methodological approaches are important, as our findings have pointed out, for protecting the most vulnerable from RSV.